Single priming and booster dose of ten-valent and 13-valent pneumococcal conjugate vaccines and Streptococcus pneumoniae colonisation in children in South Africa: a single-centre, open-label, randomised trial

Streptococcus pneumoniae and other bacterial nasopharyngeal colonization seven years post-introduction of 13-valent pneumococcal conjugate vaccine in South African children

“…Of interest, we recently reported that a one-dose primary series of PCV13 and booster dose (14 and 40 weeks of age) yielded higher anti-19F IgG compared with the two-dose and booster schedule currently used in South Africa (6, 14, and 40 weeks of age). Furthermore, the 1+1 schedule was associated with 2.89-fold lower prevalence of 19F colonization at 15 months of age compared with the 2+1 schedule, suggesting that transitioning to a 1+1 schedule could assist in reducing the residual prevalence of 19F colonization in settings such as South Africa [27] .…”